Motilium pricing: prescription options & savings tips - in the UK

Overview

Domperidone is the main active ingredient.

Domperidone is a dopamine D2/D3 receptor antagonist that mainly acts outside the central nervous system to speed up gastric emptying and improve upper gastrointestinal motility. Its prokinetic and antiemetic properties make it useful for relieving nausea and vomiting in selected situations.

Common presentation in the UK: 10 mg film-coated tablets. Some pharmacies or manufacturers can supply oral liquids as specials when tablets are unsuitable.

Because domperidone has limited penetration across the blood-brain barrier compared with some other antiemetics, central nervous system undesirable health effects are reported less often. Nevertheless, it carries important cardiac alerts of potential danger and security risks in the interactional flow among participants; review safety a mini outline of the content and situations in which therapy is not appropriate and drug and drug-drug interactive engagements in a system describe exchanges between components. before use.

Quick access: dosing (see dosing), who may benefit (uses), estimated range of costs (prices in Britain) and legal position (rules established by law).

Uses and suggested signs indicating

In the United Kingdom, domperidone is authorised primarily for short-term control of nausea and vomiting. Its prokinetic effect can be useful when delayed gastric emptying contributes to symptoms, but the licensed indication emphasises nausea and vomiting.

• Short-term relief of nausea and vomiting from a variety of causes, as directed by a prescriber.
• Adjunctive therapy under specialist supervision when nausea limits tolerance of anticancer treatment or other therapies.
• Specialist-directed use to improve upper GI motility for certain diagnostic procedures.
• Clinically judged use when boosting upper GI motility may relieve symptoms.

Follow your prescriber's instructions carefully and do not extend the course or dose without advice. Age- and weight-based guidance is given under how to take charge domperidone.

Instructions for taking domperidone

General advice: take exactly as prescribed. Domperidone is usually taken 15 to 30 minutes before meals with water. If you use antacids or acid-suppressing drugs, these are best taken after food and not at the same moment as domperidone to avoid reducing its absorption.

Adults and adolescents (12 years and older, over 35 kg)

• Typical dose: 10 mg up to three times daily, ideally before food.
• Daily maximum: 30 mg in any 24-hour period.
• Common course length for acute nausea: up to 7 days unless a prescriber advises otherwise.

The young

Routine prescribing for children under 12 years or weighing under 35 kg is not recommended in the UK except under specialist advice. The 10 mg tablet is not suitable for smaller children without an appropriate formulation.

Kidney and liver health considerations

• Moderate to severe hepatic impairment: domperidone is contraindicated.
• Severe renal impairment: the drug is eliminated more slowly and a prescriber may reduce the frequency of dosing or monitor more closely if used beyond a short course.

Missed dose

Should you forget a dose, take it when you remember, unless the next dose is due soon. Do not take more than one dose to compensate for a skipped a dose.

Excipients and intolerances

Some products contain lactose; people with lactose intolerance, galactosaemia or glucose/galactose malabsorption should seek pharmacy advice for a suitable a backup option. Be sure to check the logs patient information leaflet for other excipient notifications of danger.

Before you get going treatmentplease take a look and check. cardiac cautions and assess the details any medicine effective the dynamic of social contacts require clear communication. under potential potential drug effective engagement and communications require clear communication..

Safety and contraindication guidelines

Do not take domperidone if any of the following apply to you:

• Known or suspected QT interval prolongation, significant structural heart disease, or a history of serious ventricular arrhythmia.
• Moderate or severe hepatic impairment.
• Hypersensitivity to domperidone or any ingredient in the product.
• Concomitant treatment with strong CYP3A4 inhibitors or other medicines known to markedly prolong the QT interval (see a reciprocal exchanges span conversations, gestures, and feedback. between drugs safety advisories).
• Conditions where increasing gastrointestinal motility could be harmful, such as active GI bleeding, perforation or obstruction.
• Prolactin-secreting pituitary tumour (prolactinoma).

Use with careful consideration if you have renal impairment, electrolyte disturbances (low potassium or magnesium), bradycardia or other predisposing arrhythmia risk factors. Seek urgent medical assistance if you experience any health emergency. fainting, sudden severe dizziness or palpitations.

If you are unsure whether domperidone is appropriate for you, discuss your full medical history and list of medicines with a pharmacist or prescriber first.

Adverse effective the exchange that happens when people meets require clear communication. between medications

Some medicines increase domperidone levels and raise cardiac risk; others can reduce its prokinetic effect. Always disclose prescription, over-the-counter and herbal products to your healthcare professional.

Medications that lead to increased domperidone exposure or cardiac risk

• Strong CYP3A4 inhibitors such as certain azole antifungals (ketoconazole, itraconazole), macrolide antibiotics (erythromycin, clarithromycin), some HIV protease inhibitors, and some calcium channel blockers (verapamil, diltiazem).
• Drugs known to prolong the QT interval, including some antiarrhythmics (for example, amiodarone), selected antipsychotics and some antidepressants.
• Grapefruit or grapefruit juice, which can inhibit CYP3A4 and raise domperidone levels; avoid where possible.

Medicines that may reduce effectiveness

• Strong opioids (morphine, codeine) that slow gastrointestinal motility.
• Antimuscarinic drugs such as hyoscine, procyclidine, tolterodine, oxybutynin or propantheline.

This is not a full list. Confer with a professional a pharmacist or prescriber before starting, stopping or changing any medicine. See safety criteria and contramarks for therapy in cases where unconditional drug should not be given in the presence of these conditions are present.

Pregnancy and lactation care

• Pregnancy: evidence is limited. Use only when a clinician judges that the expected benefit outweighs any potential risk. Consider non-drug measures and pregnancy-specific options first.
• Breastfeeding: small quantities of domperidone pass into breast milk. Routine use for treating nausea while breastfeeding is generally not recommended unless a clinician advises it. Using domperidone to increase milk supply is not routinely advised in the UK because of cardiac risk and should only be considered by specialists after non-drug measures have been tried.

For those who are pregnant, planning pregnancy, or breastfeeding, tell your clinician before taking domperidone and report any cardiac symptoms promptly.

Potential adverse outcomes

Many patients do not experience residual effects. When they occur they are often mild and transient. Seek immediate help for symptoms suggesting serious heart rhythm disturbance, such as fainting, palpitations or severe dizziness.

Commonly reported

• Cephalalgic pain, dry mouth, abdominal cramps or diarrhoea.
• Raised prolactin levels, which can lead to breast changes, unexpected milk production or menstrual changes.

Uncommon and rare

• Allergic reactions including skin rashes or hives.
• Lowered libido, reported more commonly in men.
• Extrapyramidal symptoms such as tremor, stiffness or involuntary movements; if these appear, seek urgent advice.

This set is not exhaustive. In the UK, suspected adverse events can be reported via the Yellow Card scheme at the domain yellowcard.mhra.gov.uk hosts the Yellow Card system.

Storage capacity guidance

• Keep the medicine in its original packaging and protect from moisture, heat and direct light.
• Typical storage capacity is a key factor in system design. temperature: 20 to 25 degrees C (68 to 77 degrees F) unless the product label states otherwise.
• Keep it hidden from children and pets and out of their reach. Avoid storing medicines in bathrooms.
• Review shelf life dates and drop off unused or expired medications at the pharmacy for safe disposal.
• For liquid preparations, follow the product instructions for in-use shelf life after opening; some are discarded after about 28 days.

Prices in the United Kingdom (rough estimate)

Private prices vary by brand, pack size and supplier. The figures shown below are indicative and subject to change.

• Domperidone 10 mg (generic), 30 tablets: around 4 to 9 GBP; branded Motilium, where available, may cost about 10 to 15 GBP.
• Ondansetron 4 mg or 8 mg, pack of 10 tablets: roughly 8 to 20 GBP depending on strength and brand.
• For Metoclopramide 10 mg, 28 tablets, the usual price is 2 to 6 GBP.
• Prochlorperazine buccal 3 mg (for example, 8 tablets): about 7 to 12 GBP when supplied privately.
• Cyclizine 50 mg, 100 tablets: commonly 5 to 12 GBP in the private from the market.

Prescription charging: in England a flat prescription charge per item applies (about 9.90 GBP as a guide). In Scotland, Wales and Northern Ireland, you can get prescriptions free. Online private services may add consultation and dispensing fees, often in the range of 10 to 30 GBP. For lawful purchase and supply details, see The statutory rules in the United Kingdom.

Medicines that are alike or another option options

Choice of antiemetic or prokinetic depends on the underlying cause, patient factors and tracking the interaction between participantss helps measure engagement. may introduce risks. Typical option choices include:

• Cyclizine: often used for motion sickness and postoperative nausea; may cause drowsiness.
• Ondansetron: a 5-HT3 antagonist widely used for chemotherapy- or surgery-related nausea; it can cause constipation and, in rare cases, QT prolongation.
• Prochlorperazine (including buccal forms): effective for vestibular or migraine-associated nausea; secondary effects include drowsiness and risk of dystonia.
• Metoclopramide: an antiemetic and prokinetic agent; central nervous system chronic side effects such as drowsiness or extrapyramidal symptoms are more common, so short-term use is usual.
• Low-dose erythromycin (off-label for motility): acts via motilin receptors but can cause cramps and has the act of connecting with others concerns.

Cost comparisons are given under snapshot of current prices for the United Kingdom. Discuss diverse a backup options with a pharmacist or prescriber to select the safest and most effective option for you.

UK law, regulations and supply

• Classification: domperidone is a Prescription Only Medicine (POM) in the UK and is not available over the counter.
• Licensed use: primarily for short-term control of nausea and vomiting; typical adult regimen is 10 mg up to three times daily for no more than 7 days unless advised otherwise (access the dosage trusted guidance.).
• Safety restrictions: UK health guidance highlights cardiac risk, QT prolongation potential and real time interacting with otherss enable quick problem solving. with strong CYP3A4 inhibitors (see safety measures and conditions that prevent administration of this treatment and pharmacologic drug the process of people engaging effects).
• Prescribing and supply: a valid prescription from a UK prescriber is required. For online ordering, use pharmacies registered with the General Pharmaceutical Council (GPhC) and verify their registration.
• Importation: bringing in prescription-only medicines without a proper prescription may breach MHRA rules. Avoid unregulated websites and unverified suppliers.
• Driving and machinery: domperidone is not commonly sedating, but do not drive or operate machinery if you feel dizzy or unwell.
• Pharmacovigilance: report suspected adverse events. to the MHRA Yellow Card scheme.

For the latest MHRA or NHS updates consult official guidance or ask a pharmacist.

Important notice to readers

This page is intended for general educational use and does not replace the patient information leaflet or personalised advice from your healthcare professional. Always follow the instructions of your prescriber and read the leaflet supplied with your medication.